<DOC>
	<DOC>NCT01443650</DOC>
	<brief_summary>Primary Objective: Injection Site Tolerability Secondary Objectives: - To assess the safety profile of alirocumab SAR236553 (REGN727) - To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)</brief_summary>
	<brief_title>Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects</brief_title>
	<detailed_description>Total duration for each subject (not including screening) will be approximately 85 days.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Serum LDLC levels &gt;100 mg/dL. Exclusion criteria: Subjects indicated for the use of statins according to criteria in Adult Treatment Program (ATP) III Guidelines, as updated in 2004. Initiation of a new diet or major change to a previous diet within 4 weeks prior to Screening. Subjects must be willing to maintain a consistent diet for the duration of the study. Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening, including but not limited to statins, cholesterol absorption inhibitors, fibrates, niacin, bile acid resins, or red yeast rice. Fasting serum triglycerides &gt;200 mg/dL measured after an 812 hour fast. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>